reproxalap — NDA/BLA filed

“the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025.”